evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2 questions · 7 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 42.9%Moderate 4 · 57.1%High 0 · 0%

Mesalamine (4 ‐ 4.5 g/day) vs budesonide

Induction of clinical remission (CDAI < or = 150) · patients with Induction of remission or response in Crohn's disease

Mesalamine (4 ‐ 4.5 g/day) may leads to lower induction of remission (CDAI < or = 150) ‐ Pentasa (4 g/day) compared with budesonide (low certainty).

2 findings from 1 review

Delayed‐release mesalamine (3 ‐ 4.5 g/day) vs corticosteroids

Induction of remission (CDAI < or =150 with or without decrease of at least 60 points) · patients with Induction of remission or response in Crohn's disease

Delayed‐release mesalamine (3 ‐ 4.5 g/day) showed no clear difference in induction of remission (CDAI < or =150 with or without decrease of… compared with corticosteroids (moderate certainty).

5 findings from 1 review
Show 2 more findings